Adaptate Biotherapeutics raises $18 million in Series A2 funding
London, UK... Adaptate Biotherapeutics, a company focused on developing antibody-based therapeutics for modulation of gamma delta T cells, today announced that its existing investors, Abingworth and Takeda Pharmaceutical Company Limited have together made a further equity investment of $18 million (circa. £13 million). This funding brings the total raised since Adaptate’s inception in late…
ERS Genomics and NUVISAN ICB sign CRISPR/Cas9 licence agreement
CRISPR offerings to enhance NUVISAN’s drug development service portfolio.
Arkema chooses Dotmatics as R&D digitalization partner
Bishop’s Stortford, UK: Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has been selected by Arkema, a global leader in speciality materials, as its informatics partner in an R&D digitalization project. Implementing Dotmatics’ unified…
FairJourney Biologics enters next-generation antibody discovery collaboration with argenx
Porto, Portugal, and Cambridge and London, UK: FairJourney Biologics S.A (FJB) and IONTAS Limited (IONTAS), leaders in the discovery and optimisation of VHH fully human antibodies, today announced a collaboration with global immunology company, argenx to harness IONTAS’ proprietary mammalian display technology. The goal of the collaboration is to explore diverse panels of novel antibody…
Mologic’s COVID-19 rapid antigen self-test selected by NIH for RADx initiative funding
Mologic, a leading developer of lateral flow and rapid diagnostic technologies, announced its rapid antigen self-test for COVID-19 has been selected by the Rapid Acceleration of Diagnostics (RADxSM) initiative launched by the US National Institutes of Health (NIH). The initiative aims to speed innovation in the development, commercialisation, and implementation of technologies for COVID-19…
Avacta announces distribution agreement with Abcam plc
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that it has entered into a global distribution agreement with Abcam plc (AIM: ABC; NASDAQ: ABCM) to sell the Group’s recently developed SARS-CoV-2 research ELISA Affimer® reagents.
Dotmatics implements ‘Data to Value’ initiative with BASF Agricultural Solutions
Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced the implementation of a ‘Data to Value’ initiative with BASF’s Agricultural Solutions division.
Insightful Science joins forces with Dotmatics to form a leading cloud-first scientific R&D company
Bishop’s Stortford, UK and San Diego, CA— Insightful Science, a leading software provider serving the global life sciences community, announced that it has entered into a transaction to acquire Dotmatics, an industry leading cloud-based scientific R&D data management platform.
IONTAS identifies novel SARS-CoV-2 neutralising antibodies
Cambridge, UK, Porto, Portugal, and London, UK – IONTAS Limited and FairJourney Biologics SA (FJB), leaders in the discovery and optimisation of fully human antibodies, have announced the identification of neutralising antibodies, which bind to multiple emerging SARS-CoV-2 variants.
Aptamer Group and Mologic enter commercial partnership to develop aptamer-based SARS-CoV-2 rapid antigen test
York and Bedfordshire, UK...Aptamer Group, the developer of diagnostic and therapeuticOptimer reagents, today announced a commercial partnership with Mologic, a leading developer and manufacturer of lateral flow and rapid diagnostic tests.
Axol Bioscience and Censo Biotechnologies announce merger
Axol Bioscience Ltd, an established provider of iPSC-derived cells, media, and characterisation services, and CENSO Biotechnologies, a cell biology CRO with focused expertise in iPSC-related technologies, today announced that the two companies have signed a merger agreement.
ERS Genomics and Setsuro Tech sign CRISPR/Cas9 licence agreement
Nobel prize winning CRISPR technology to be applied in development of genetically engineered cell and animal models.
IONTAS and FairJourney Biologics enter antibody discovery agreement with Quell Therapeutics
Cambridge, UK, Porto, Portugal, and London, UK – 08 March 2021: IONTAS Limited and FairJourney Biologics S.A (FJB)., leaders in the discovery and optimisation of fully human antibodies, have announced that they have entered into an agreement with Quell Therapeutics Limited regarding IONTAS / FJB’s proprietary libraries and technology platforms.
Nonacus introduces Whole Genome Sequencing service to support SARS-CoV-2 testing laboratories
Birmingham, UK: Nonacus, a provider of genetic testing products for precision medicine and liquid biopsy, today announced the commercial launch of a new service for Whole Genome Sequencing of SARS-CoV-2, developed to enable the UK government’s Test-To-Release scheme. Assay development for the new service was funded by a grant from Innovate UK, the UK’s innovation agency.
Avacta’s rapid antigen test is confirmed to detect SARS-CoV-2 new variants
Avacta’s AffiDX SARS-CoV-2 lateral flow test detects both B117 ‘Kent’ and D614G variants of the virus.
Dotmatics announces licensing agreement for informatics software with Compugen
Bishop’s Stortford, UK, 3rd March 2021: Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, today announced it has entered a licensing agreement with Compugen, a clinical-stage drug discovery and development company focused on immuno-oncology. The multi-year agreement…
ERS Genomics licenses CRISPR gene editing technology to Otsuka Pharmaceutical
Licence to Nobel prize winning CRISPR technology supports internal research and development.
WuXi AppTec completes acquisition of OXGENE
PHILADELPHIA and OXFORD, March 2, 2021 - WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy…
ERS Genomics expands team with appointment of Jon Kratochvil as VP Business Development
DUBLIN, Ireland, 01 March 2021: ERS Genomics Limited (ERS), which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced the appointment of Jon Kratochvil as Vice-President for Business Development & Licensing for North America.
ERS Genomics and G+FLAS Life Sciences sign CRISPR/Cas9 licence agreement
Dublin, Ireland and Seoul, Korea, 23 February 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and G+FLAS Life Sciences, Inc. (G+FLAS), a biotechnology company developing research tools and reagents associated with CRISPR technology, today announced a non-exclusive licence agreement…
Optibrium appoints Dr Rae Lawrence as Director of Software Development
Optibrium™, a developer of software for drug discovery, today announced the appointment of Dr Rae Lawrence as Director of Software Development. With the continued success of the Company’s portfolio of cheminformatics and AI-based drug discovery software, and the recent backing by Kester Capital, Optibrium has made the new appointment to drive its product development agenda. Rae will focus on…
Cell Guidance Systems’ nanoparticle cytokines enable use of macrophages to treat disease
Cell Guidance Systems Ltd, a specialist in the control, manipulation and monitoring of cells, both in vitro and in vivo, today announced its POlyhedrin Delivery System (PODS) technology has been shown to modulate macrophage secretion profiles with therapeutic potential. The results of this research are available as an unpublished preprint in bioRxiv1.
Avacta announces phase 1 Clinical Trial Authorisation (CTA) for AVA6000 approved by MHRA
Cambridge and Wetherby, 18 February 2021: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, announces that it has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) for its Clinical Trial Authorisation (CTA) in the UK for a phase I study of its lead pre|CISION™ pro-drug, AVA6000 pro-doxorubicin.
ERS Genomics and ZeClinics sign CRISPR/Cas9 licence agreement
Dublin, Ireland & Barcelona, Spain, 16 February 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier, and ZeClinics, a contract research organization using zebrafish to carry out services focused on analysing the safety, efficacy and biomedical relevance of new compounds, today…
Avacta announces results of initial evaluation of SARS-CoV-2 lateral flow antigen test with clinical samples
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, announces that it has received the first data for its SARS-CoV-2 rapid antigen test from ongoing clinical studies in Europe and the UK. These data show excellent performance of the test in identifying patients with an infectious viral load and no false positive results.